About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: SCMP
- CUSIP: 86490910
- Previous Close: $11.75
- 50 Day Moving Average: $11.77
- 200 Day Moving Average: $12.86
- 52-Week Range: $42,818,000.00 - $9.59
- Trailing P/E Ratio: 39.70
- Foreward P/E Ratio: 6.99
- P/E Growth: 0.69
- Market Cap: $503.11M
- Outstanding Shares: 42,818,000
- Beta: 1.74
- Net Margins: 6.29%
- Return on Equity: 44.19%
- Return on Assets: 10.98%
Companies Related to Sucampo Pharmaceuticals:
- Debt-to-Equity Ratio: 1.36%
- Current Ratio: 3.56%
- Quick Ratio: 3.19%
What is Sucampo Pharmaceuticals' stock symbol?
Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."
Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 12 month target prices for Sucampo Pharmaceuticals' stock. Their predictions range from $15.00 to $29.00. On average, they anticipate Sucampo Pharmaceuticals' share price to reach $18.29 in the next year.
When will Sucampo Pharmaceuticals announce their earnings?
Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Sucampo Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:
According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Amitiza's solid prescription growth so far this year demonstrates persistently robust demand. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. However, Sucampo’s dependence on Amitiza for growth is concerning. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. Shares of the company have underperformed the Medical-Drugs industry in the past one year." (2/21/2017)
Jefferies Group LLC analysts commented, "SCMP reported Q4 EPS of $0.23 (vs $0.19 JEFe) on revs of $55M – which included 2 months of R-Tech contributions ($11.8M) despite a Dec 7 close and a $5M payment from MYL. Excluding these items, revs reached $38.6M (+36% Y/Y) – slightly ahead of our $37.9M est. Mgt reaffirmed its FY16 guidance and sees 5 key data readouts this year. We remain constructive on mgt’s ability to deliver value creating M&A – which remains the key to significant share appreciation. Despite Managed Care Change, Amitiza Still Poised for Low Double Digit Growth: While Amitiza lost preferred formulary status at Caremark on Jan 1, partner Takeda deployed a zero copay card in late FY15 to bolster patient access. Rxs have stabilized, posting mid-single digit Y/Y gains YTD (vs 9.8% in 4Q15). Mgt indicated that they are somewhat insulated from potential pricing headwinds as SCMP’s contract with Takeda caps its GtN exposure at 20%. Including a 5% price increase on Jan 1, Amitiza remains poised for low double digit growth this year. With an Amitiza settlement (FTF Par) already in place, SCMP plans to vigorously defend its IP from Dr. Reddy’s." (3/9/2016)
Maxim Group analysts commented, "Sucampo reported 4Q revenues of $55M vs. $33M in the prior quarter, with the increase being driven by both the R-Tech Ueno acquisition and strong Amitiza revenues (20% plus). GAAP net income was reported $10M or $0.23 per share. On an adjusted (Non-GAAP) basis the company had $19M in net income." (3/9/2016)
Who owns Sucampo Pharmaceuticals stock?
Sucampo Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ryuji Uen (23.00%), Sachiko Kun (23.00%), Sachiko Kuno Foundation, Inc (5.20%), Dimensional Fund Advisors LP (3.64%), Renaissance Technologies LLC (3.41%) and Royce & Associates LP (1.83%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Anthony C Celeste, Daniel P Getman, Matthias Alder, Peter Greenleaf, Thomas J Knapp and William Ashton.
Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?
Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC, GSA Capital Partners LLP, AQR Capital Management LLC, FMR LLC, Pacad Investment Ltd. and Renaissance Group LLC. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf.
Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?
Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Stonepine Capital Management LLC, Royce & Associates LP, State Street Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Tudor Investment Corp Et Al and Clark Capital Management Group Inc..
How do I buy Sucampo Pharmaceuticals stock?
Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sucampo Pharmaceuticals stock cost?
One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $11.75.